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Cognitive impairment (CI) in amyotrophic lateral sclerosis (ALS) may present a serious
barrier to a patient’s wellbeing and significantly decrease quality of life. Although reports of
CI in ALS without frank dementia are becoming quite common, questions remain regarding
the specific cognitive domains affected, as well as how other psychological and medical
factors may impact cognitive functioning in these patients. Additionally, the influence of
depressive symptoms on disease processes is not known. We aimed to address these
questions by completing extensive neuropsychological tests with 22 patients with ALS
and 17 healthy volunteers. A subgroup of these patients also completed questionnaires
to measure depressive and vegetative symptoms. We tested for overall cognitive dif-
ferences between groups, the influence of physical (e.g., bulbar and limb), vegetative
(e.g., fatigue), and depressive symptoms on cognitive performance, and the relationship
between depressive symptoms and disease severity in ALS. Overall, patients performed
more poorly than healthy controls (HCs), most notably on tests of executive functioning
and learning and memory. Results suggest that true cognitive performance differences
exist between patients with ALS and HCs, as these differences were not changed by the
presence of vegetative or depressive symptoms. There was no effect of limb or bulbar
symptoms on cognitive functioning. Also, patients were not any more depressed than
HCs, however increased depressive scores correlated with faster disease progression and
decreased limb function. Collectively, it is suggested that translational advances in psy-
chological intervention for those with CI and depression become emphasized in future
research.
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INTRODUCTION
Until recently, amyotrophic lateral sclerosis (ALS) was still con-
sidered by many a pure motor neuron disease (Pongratz, 2000),
and the notion of cognitive impairment (CI) in ALS was met with
much resistance until just the past several years (Bak and Chan-
dran, 2012). It is now widely accepted that ALS is a multisystem
disorder involving CI in approximately 30% of those diagnosed
with the disease (Rippon et al., 2006). ALS with CI is now recog-
nized as a subcategory of ALS (Strong et al., 2009) and is denoted
as ALSci (Murphy et al., 2007), which entails presentation of CI
without frank dementia. Importantly, some experts propose that
ALS is not a categorical disease, but rather a spectrum disorder
between pure ALS and Frontotemporal Lobar Degenerative dis-
eases, such as Frontotemporal dementia (Abrahams et al., 2000;
Grossman et al., 2007; Murphy et al., 2007; Woolley and Katz,
2008; Merrilees et al., 2010).
Recent advances in the field support the need for study into
cognitive problems associated with ALS (see Phukan et al., 2007).
One critical reason for this research is that cognitive difficul-
ties in patients with ALS negatively impact quality of life, and
appear to be even more detrimental to quality of life than physical
impairment (Goldstein et al., 2002). Personal communication with
patients who believe their cognitive ability has been compromised
report being negatively impacted by these symptoms and wanting
help, or at least support, in this area. Additionally, CI can influ-
ence decision-making (Girardi et al., 2011), treatment compliance
(Olney et al., 2005), survival (Olney et al., 2005; Flaherty-Craig
et al., 2011), and even the wellbeing of caregivers (Merrilees et al.,
2010).
Most studies that have identified CI in patients with ALS have
utilized a comprehensive neuropsychological battery to assess
performance across multiple modalities. Of these studies, ver-
bal fluency remains one of the most sensitive measures for CI,
repeatedly showing poorer performance in those with ALS com-
pared to healthy individuals (Abrahams et al., 1997, 2000; Kilani
et al., 2004; Grossman et al., 2007). These findings hold even after
correcting for possible verbal production impairment (Abrahams
et al., 2004). Other studies have found decreased performance in
other areas of executive function (Kilani et al., 2004), memory
(Abrahams et al., 1997; Hanagasi et al., 2002), and language (Hillis
www.frontiersin.org December 2012 | Volume 3 | Article 542 | 1
Jelsone-Swain et al. Cognition and depression in ALS
et al., 2004; Raaphorst et al., 2010). Although reports of CI in
ALS are becoming more common, characteristics of ALSci are not
well defined due to a number of factors. These include the lack
of availability of valid cognitive measures that can be adminis-
tered to ALS patients with significant motor or speech limitations,
as well as minimal research focusing on additional variables that
could also impact cognition, such as physical symptoms and mood
state.
As previously mentioned, ALSci is not well understood, and
the involvement of physical symptoms on CI in ALS is not known.
Specifically, previous research has indicated that those with bulbar
onset are more likely to have ALSci (Gordon et al., 2011), yet others
have not supported this notion (Rusina et al., 2010). Additionally,
vegetative physical symptoms of ALS may impact the interpreta-
tion of those identified with ALSci. For example, it is known that
fatigue, one of the most common vegetative symptoms in ALS,
interferes with cognitive test performance in other patient groups
(Diamond et al., 2008). For the purpose of this paper, vegetative
symptoms collectively refer to changes in concentration, fatigue,
appetite, sleeping, and energy level. Although these symptoms can
also be specific to depression, ALS patients with physical weakness
are likely to have more vegetative symptoms in the performance of
daily activities rather than from depression, especially if the patient
does not report other symptoms of depression such as hopeless-
ness and guilt. Therefore, it is necessary to differentiate between
physical and depressive symptoms in predicting CI in order to
obtain a more accurate description of CI in patients with ALS.
This may also lead to more streamlined classification of those with
true CI who may need or want intervention.
Like CI, research suggests that depressive symptoms in ALS
may also have a negative impact on many aspects of quality of life
(Tramonti et al., 2012), and could potentially affect cognition. To
our knowledge however, no studies have examined the influence
of depressive symptoms on cognitive performance in ALS. Like
vegetative symptoms, mood status could present a potential con-
found in the diagnosis of ALSci. Also, depressive symptoms may
increase the risk of having CI, or differentially affect cognition
in patients with ALS compared to a healthy control population.
These situations are likely, as depression can negatively influence
cognitive performance in other diseases (Diamond et al., 2008;
Sassoon et al., 2012).
The relationship between depression and prognosis or physical
symptom presentation in ALS is another area of research that has
received little attention, possibly due to the general report of a
global positive psychosocial adjustment in these patients (Brown
and Mueller, 1970; Lulé et al., 2012). Despite this view, prevalence
rates of depression (McLeod and Clarke, 2007) and reports on the
effect of depression on ALS are not consistent. For example, Atassi
et al. (2011) reported no relationship between disease progres-
sion and depression, yet a previous study identified a significant
negative impact of psychological distress on mortality outcome
(McDonald et al., 1994). Using the ALS Functional Rating Scale
(ALSFRS), a group in South Korea found that decreased phys-
ical functioning correlated with depressive symptoms (Oh et al.,
2012), highlighting the importance of examining this relationship.
Patients in this study however were on average both highly physi-
cally disabled (ALSFRS mean score of 19) and many were clinically
depressed (Beck Depression Inventory mean score of 24.5). If con-
sistent evidence supports the association of depressive symptoms
with disease processes (especially while patients are still early in
the disease course and without clinical depression), this would
bring about new emphasis into the study of depression in ALS,
ultimately leading to improved identification of those at highest
risk and thus early intervention.
The overall goal of this study was to recognize if cognitive sta-
tus is affected in patients with ALS early in their disease course
and without severe clinical depression. We also examined other
variables that may be associated with cognitive performance that
could either facilitate in future early screening or confound the
diagnosis of ALSci. Specifically, we investigated the relationship of
physical impairment, vegetative symptoms, and depressive symp-
toms on cognitive functioning. In addition, we tested whether
depressive symptoms are associated with disease progression or
physical impairment. We utilized standard neuropsychological
tests to measure these relationships. Based on previous literature,
we hypothesized that patients with ALS would perform at a lower
level on tests within the neuropsychological battery, especially
those targeting executive functioning skills. We predicted that
physical, vegetative, and depressive symptoms would negatively
influence cognitive performance, but that these would not be con-
founding variables in performance differences between patients
with ALS and healthy volunteers (suggesting true cognitive impair-
ment in the ALS group). We also hypothesized that ALS patients
would have more depressive symptoms than healthy controls, and
that increased depressive symptoms would be related to disease
severity.
MATERIALS AND METHODS
PARTICIPANTS
Twenty-two patients with ALS participated in this study. All
patients were recruited through the ALS Clinic at the University of
Michigan. Patients were diagnosed by a neuromuscular physician
at the University of Michigan using the El Escorial criteria for ALS.
Enrolled patients were engaged in a larger longitudinal neuroimag-
ing component of this study; therefore all patients were without
any contraindications to magnetic resonance imaging (MRI), were
able to lay flat on their back without respiratory distress, were not
dependent on artificial ventilation, and were ambulatory. Twenty-
three healthy controls (HCs) were recruited through the general
community from an internet-based recruitment tool (UMClini-
calTrials.org) and from flyers posted around the Ann Arbor, MI
area. Participants were excluded from either group if they had a
history of alcohol or drug abuse, neurological disease (other than
ALS), were ever diagnosed with a psychological disorder, or were
severely clinically depressed at the time of their participation. No
patient was excluded from the study, and one healthy volunteer was
excluded for major depression. Because we aimed to compare cog-
nitive status in patients with ALS to a truly healthy control group,
HCs at risk for mild CI (see Statistical Analysis) were also excluded
from the final analysis. Participant demographic information for
these final groups is displayed in Table 1. Signed consent from
each participant was obtained, and all aspects of this study were
approved by the Institutional Review Board at the University of
Michigan.
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Table 1 | Means and SD for demographic information by group.
Demographic variables ALS patients Healthy controls
Age 59 (6.6) 58 (5.0)
DH 18R*, 4L 15R, 2L
Sex 13M, 9F 5M, 12F
Education years 13.4 (2.0) 16 (2.6)
Symptom onset 17L, 5B NA
ALSFRS-r total 37.2 (6.9) NA
ALSFRS-r limb 16.5 (5.3) NA
ALSFRS-r bulbar 10.0 (2.4) NA
ALSFRS-r resp. 10.73 (1.9) NA
MSO 26.2 (35.6) NA
DH, dominant hand; Education Years, number of complete years of educa-
tion, considering degrees obtained; ALSFRS-r Limb, subscore from ALSFRS-r
questionnaire assessing limb function (questions 4–9); ALSFRS-r Bulbar, sub-
score from ALSFRS-r questionnaire assessing bulbar function (questions 1 – 3);
ALSFRS-r Resp., subscore from ALSFRS-r questionnaire assessing respiratory
function (questions 10 – 12); MSO, months since symptom onset. *Two patients
reported current dominant hand as a result of disease processes and not by
preference.
NEUROPSYCHOLOGICAL ASSESSMENTS
All participants completed a 60-min neuropsychological battery
designed by a team of neuropsychologists experienced in motor
diseases (lead by CP). These tests were selected to assess a broad
range of cognitive skills, particularly those commonly associated
with frontotemporal dementia, given the reported prevalence of
such deficits in patients with ALS. Depressive and vegetative symp-
toms were also measured using the Geriatric Depression Scale,
short version (GDS), and the Beck Depression Inventory (BDI),
respectively. Not all participants completed both questionnaires.
Nineteen ALS patients and 15 HCs completed the GDS, and 14
patients and 15 HCs completed the BDI. All tests and question-
naires are described below. Reliability coefficients and, when avail-
able, construct validity coefficients are given for each measurement
(Strauss et al., 2006).
Mini-Mental State Examination (Folstein et al., 1975)
The Mini-Mental State Examination (MMSE) is a brief test of
global cognitive function and is often used as a screen for demen-
tia. The scale assesses a subject’s orientation to time and place,
instantaneous recall, short-term memory, and ability to perform
serial subtractions or reverse spelling. The MMSE also measures
constructional capacities (the ability to copy a design) and the use
of language. Internal consistency of this test ranges between 0.31–
0.96, test re-test reliability ranges between 0.80–0.95, and construct
validity is modest to high in correlating with other similar tests.
Hopkins Verbal Learning Test (Shapiro et al., 1999)
The Hopkins Verbal Learning Test (HVLT) is a learning and mem-
ory test that measures initial recall (test re-test reliability 0.74),
delayed recall (20 min, test re-test reliability 0.66), and discrimi-
nation recall (test re-test reliability 0.40) for a list of words read by
the administrator. The test is available in multiple alternate forms
with a moderate to high construct validity with other similar tests.
Faces Subtest: Wechsler Memory Scale (WMS-III; subtests – Faces)
(Wechsler, 1997)
Faces is a test of visual learning and recognition memory for pic-
tures of faces. There is an initial recall test (Faces I) and a delayed
recall test (Faces II, 30 min after first exposure to the set of faces).
Internal reliability for these tests is between 0.60–0.96, internal
consistency is between 0.70–0.79, and construct validity is modest.
Boston Diagnostic Aphasia Examination: Complex Ideational
Material (Goodglass and Kaplan, 1983)
The Complex Ideational Material (CIM) subtest of the Boston
Diagnostic Aphasia Examination (BDAE) measures auditory com-
prehension. This task requires patients to understand and express
agreement or disagreement concerning factual material that are
derived from inference. Complex Ideational Material has an inter-
nal consistency of 0.80 and a construct validity score between 0.86
and 0.93. This test was originally designed for patients with apha-
sia, so test-re-test reliability measurements were not provided as
test performance is expected to change with this group.
The Boston Naming Test (Kaplan et al., 1978)
The Boston Naming Test (BNT) is a confrontation-naming test
that is largely used to measure language processing. The test
consists of 60 large pen and ink drawings of items ranging in
familiarity. Participants are asked to freely name each item. If
the identity of an item is not known, first a stimulus cue is pro-
vided, then a phonemic cue if needed. Scores used in this study
only include freely identified and stimulus-cued correct responses.
Internal consistency coefficients range between 0.78–0.96 and test
re-test reliability is high (0.91). Construct validity is also high.
Judgment of Line Orientation (Benton, 1983)
The Judgment of Line Orientation (JOLO) measures visuospa-
tial ability, specifically the ability to estimate angular relationships
between line segments by visually matching angled line pairs to
numbered radii that form a semicircle. The internal consistency
for this test is between 0.84 and 0.91 and the test re-test coefficient
is 0.90. Construct validity is high when compared with other visual
spatial subtests.
Digit Span (Wechsler Adult Intelligence Scale: WAIS subtest)
(Wechsler, 1997)
Digit Span is a subtest from the WAIS measuring auditory working
memory. This test consists of two sections measuring immediate
recall of a forward and backward digit series. In this study the total
cumulative score of number of correct trials was used to mea-
sure overall working memory recall. Backward digit span is more
challenging and was also used as a measurement in this study.
The maximum span of backward digits recalled was used; there-
fore this measurement was not collinear with the total cumulative
score. The generalizeability coefficient for this test is high (0.80–
0.89) and the test re-test coefficient for the backward subscore is
marginal (0.60–0.69).
Oral Trail-Making Test (Lezak, 1995)
The Oral Trail-Making Tests (OTMT) are tests of processing speed
(Trails A) and conceptual ability (Trails B). For Trails A, the subject
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is required to recite consecutive numbers, from 1–25, as quickly as
possible. On Trails B, subjects are asked to alternate between num-
bers and letters, from 1-A to 13-M. Two scores for each part are
obtained – the total time and number of errors. To more accurately
measure set-shifting abilities from Oral Trail-Making Test B and
partial out motor speed due to possible verbal speed production
impairment in patients with ALS (Abrahams et al., 2000), time
(in seconds) to complete Oral Trail-Making Test B was divided by
time (in seconds) to complete Oral Trail-Making Test A, resulting
in an Oral Trails B/Oral Trails A ratio. This ratio results in a more
statistically accurate measure to account for processing speed dif-
ferences between groups. The test re-test reliability is adequate for
test A and high for test B. Tests A and B correlate well with each
other (0.31).
Controlled Oral Word Association Test (Benton, 1983)
The Controlled Oral Word Association Test (COWAT) is a test of
verbal letter fluency using the letters C, F, and L. Participants are
asked to name as many words beginning with each letter in 1 min
(each). This is largely a test of executive function. The internal
consistency for this test, specifically using the letters CFL, is high
(0.83). Test re-test reliability is high (0.70) and construct validity
is high.
Animal Naming (Sager et al., 2006)
The Animal Naming test is a categorical verbal fluency test and is
used as a test of executive function. Participants are asked to name
as many animals as they can in 1 min. Test re-test reliability is 0.56
and construct validity is moderately high.
Geriatric Depression Scale-Short Form (Yesavage and Sheikh, 1986)
This 15-(yes/no) questionnaire was developed specifically to mea-
sure depression in older adults. Symptoms common to normal
aging and those pertaining to feelings of guilt, sexual activity, sui-
cide, and somatic symptoms are not included in this questionnaire.
Rather, this questionnaire focuses on the individual’s locus of con-
trol, “. . . making this more suitable for subjects in hospital or
long-term care” (Strauss et al., 2006, p. 1104). Therefore the Geri-
atric depression scale-short form (GDS) was deemed as a more
valid measure of core depressive symptoms in the ALS group and
was used as a measure of depression severity. The short version
has a high correlation with the full version, which is moderately to
highly correlated with other tests of depression (0.73–0.91). The
internal consistency for the full version ranges between 0.71 and
0.84 and test re-test reliability is 0.84.
Beck Depression Inventory (Beck et al., 1996)
This 21-item likert-scale questionnaire is a brief self-report of
depression. The BDI contains a number of somatic and vegetative
symptoms that can overlap with physical illness, more common
in older adults and especially those with motor neuron diseases.
Therefore impetus for completing the BDI was to provide a mea-
sure of vegetative symptoms to asses show they may contribute
to cognitive functioning. Five questions were selected to describe
vegetative symptoms: 15. Loss of Energy; 16. Changes in Sleep-
ing Pattern; 18. Changes in Appetite; 19. Concentration Difficulty;
20. Tiredness or Fatigue. The internal consistency coefficient for
this questionnaire is high (0.88) and the test re-test reliability is
adequate to high (0.74–0.93). The construct validity is also high.
STATISTICAL ANALYSIS
Neuropsychological test results used to compare cognitive perfor-
mance between groups are listed in Table 2. All data is presented
in raw scores. All data were examined to check for parametric
analysis statistical assumptions. Results from two tests did not
meet these assumptions: the Complex Ideational Material (CIM)
and Oral Trails-Making Test B/A ratio scores. In the CIM, the
majority of participants performed at ceiling level (maximum
score of 12 points), with just one person scoring nine points. The
CIM was therefore excluded from further statistical models. The
Oral Trails B/A ratio score was slightly positively skewed in both
groups. Therefore individual scores from the Oral Trails B/A ratio
were transformed (using the natural logarithm function), which
resulted in a normal distribution for both groups. IBM’s statis-
tical software package SPSS, version 19, was used to conduct all
analyses.
To assure our control group consisted of truly healthy volun-
teers, z-scores from neuropsychological tests were examined for
mild cognitive impairment (MCI). Using standard criteria estab-
lished in the literature, controls were excluded for suspected MCI
if they scored at or below the fifth percentile on one or more cog-
nitive test (Royall et al., 2004; Aarsland et al., 2010). Five controls
were excluded for MCI, resulting in 17 participants in the HC
group.
Age and years of education were compared between groups
using independent sample t-tests, which showed no age differ-
ences (p= 0.65) but significantly more years of education in the
HC group [t (37)=−3.65, p< 0.01]. Therefore education was
included as a covariate in the following statistical models.
RESULTS
All patients with ALS completed the ALS Functional Rating Scale,
revised version (ALSFRS-r). The ALSFRS-r is a 12-question sur-
vey measuring physical functioning of patients with ALS and is
a strong predictor of progression and survival (Kollewe et al.,
2008). Limb, bulbar, and respiratory functioning are measured
in this scale and the maximum total score is 48 (lower scores indi-
cate decreased physical function). Mean ALSFRS-r score for this
patient group was 37.2 (SD= 6.9). Additionally, all participants
completed the Oldenfield handedness questionnaire and a head
trauma questionnaire (Armon and Nelson, 2012). Demographic
information is presented in Table 1.
COGNITIVE IMPAIRMENT IN THE ALS PATIENT GROUP
Using the consensus criteria developed by Strong et al. (2009),
individual normalized scores were examined for each patient to
identify those with possible ALSci. Scores below the fifth percentile,
or falling below a z-score of−1.6, were flagged. Individuals whose
scores fell below this cut-off on two or more distinct tests were
identified as patients with ALSci.
Examining z-scores from each of the tests within the neuropsy-
chological battery, eight of the 22 patients (36.4%) with ALS were
identified as having CI. This finding is consistent with previous
research showing an estimated 30% of patients with comorbid CI
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Table 2 | Neuropsychological test results between patients with ALS and healthy controls.
Cognitive domain Neuropsychological
test measurement
ALS patients (n=22) Healthy controls (n=17) Group differences
Mean raw
score (SD)
%
Impaired
Mean raw
score (SD)
%
Impaired
F -value p-value
Mental status/dementia screen MMSE total score 27.41 (2.04) na 27.65 (1.50) na 0.31 0.58
Executive function COWAT (CFL) total score 32.77 (9.25) 4.50 49.53 (12.62) 0.0 11.12 <0.01
Animal Naming total score 15.91 (4.22) 36.36 22.06 (4.59) 5.8 10.04 <0.01
OTMT B seconds 44.68 (29.62) 4.50 25.56 (15.49) 0.0 na na
OTMT transformed ratio (B
seconds/A seconds)
1.32 (0.55) na 1.18 (0.39) na 1.19 0.28
Memory/learning HVLT initial recall, trials 1–3 23.86 (5.82) 31.80 27.24 (4.13) 5.8 1.10 0.30
HVLT delayed recall, trial 4 8.59 (2.40) 27.3 9.94 (1.39) 0.0 1.65 0.21
HVLT discrimination score 10.18 (1.62) 18.2 11.24 (0.97) 0.0 2.68 0.11
Faces I total score 34.86 (4.81) 4.5 39.00 (4.47) 0.0 10.390 <0.01
Faces II total score 37.05 (4.87) 9.0 40.65 (2.78) 0.0 6.81 0.01
Attention/concentration Digit Span total score 15.68 (3.72) 4.5 18.12 (3.33) 0.0 2.53 0.12
Digit Span backward span 4.50 (1.06) 0.0 5.24 (1.35) 0.0 0.83 0.37
Visuoperceptual JOLO total score 23.91 (5.38) 13.63 25.88 (4.26) 5.8 0.05 0.83
Language BNT total score including
semantic cues
56.55 (2.46) 0.0 55.94 (3.15) 0.0 3.95 0.06
Depression GDS (ALS n=19, HC n=15) 2.32 (1.97) na 1.07 (1.16) na (t ) 2.17 0.04
BDI (ALS n=14, HC n=15) 5.57 (3.80) na 3.00 (2.17) na (t ) 2.26 0.03
Vegetative symptoms BDI_veg (ALS n=14, HC n=15) 2.64 (1.74) na 1.67 (1.29) na (t ) 1.73 0.10
MMSE, Mini-Mental State Exam; COWAT, Controlled Oral Word Association Test; OTMT, Oral Trail-Making Test; HVLT, Hopkins Verbal Learning Test; Faces I & II from
the Wechsler Memory Scale III; JOLO, Judgment of Line Orientation; BNT, Boston Naming Test; GDS, Geriatric Depression Scale; BDI, Beck Depression Inventory;
BDI_veg, five questions measuring vegetative symptoms taken from the BDI; % impaired, percent of participants in each group with a z-score<−1.6. Only tests
used in the identification of MCI or ALSci were included. Between group statistics from the primary MANCOVA were Bonferroni corrected for multiple comparisons
(p<0.05), education was entered as a covariate and degrees of freedom were 1, 36. Independent sample t-tests were conducted for the GDS, BDI, and BDI_veg.
GDS degrees of freedom, 32; BDI degrees of freedom, 27.
(Massman et al., 1996; Lomen-Hoerth et al., 2003; Rippon et al.,
2006; Gordon et al., 2010; Raaphorst et al., 2010; Grace et al.,
2011). Five of these patients scored at or below the threshold on
the Animal Naming test and seven scored at or below the thresh-
old on the HVLT. Scores from the Animal Naming and the HVLT
tests were also among the most impaired scores overall in the ALS
group, including scores from patients who did not meet criteria
for ALSci. Table 2 indicates the percent of patients who performed
below the fifth percentile on each measurement.
A MANCOVA was conducted to test the effect of diagnosis
group on cognitive performance, which showed a significant dif-
ference between ALS patients and HCs,F(13,24)= 4.10,p= 0.001,
η2= 0.69. There was a specific significant difference between
groups on Faces I, Faces II, COWAT, and Animal Naming. These
statistics are shown in Table 2. The overall effect of education
was not significant, F(13, 24)= 1.60, p= 0.15, η2= 0.46, however
education had an exclusive effect on the BNT, F(1, 36)= 7.04,
p= 0.012.
Because verbal fluency performance can be confounded by
speech production impairment in patients with ALS (Abra-
hams et al., 2004), we examined speed (in seconds) from Oral
Trails-Making Test A between groups. An independent sample t -
test showed that verbal speed differences approached significance,
t (37)= 1.86, p= 0.07. Therefore a second MANCOVA was per-
formed to evaluate the effect of diagnosis (ALS and HC) and
verbal production speed (Oral Trails A seconds) on verbal flu-
ency (COWAT and Animal Naming) performance. There was no
main effect of verbal speed, F(2, 34)= 1.56, p= 0.22, η2= 0.08
and no between-subjects effects of verbal speed on the Animal
Naming test,F(1, 35)= 3.07,p= 0.09, or COWAT,F(1, 33)= 1.53,
p= 0.22. There was still a main effect of diagnosis,F(2, 34)= 5.63,
p< 0.01. These results suggest that differences in verbal fluency
between groups were not confounded by verbal production speed.
PHYSICAL SYMPTOMS OF ALS DID NOT HAVE AN EFFECT ON
COGNITIVE PERFORMANCE
Physical dysfunction did not predict global cognitive summary
scores
The severity of physical dysfunction in patients with ALS may
influence cognitive test performance. Some studies found that
physical symptoms affect cognition differentially, specifically that
those with more severe bulbar symptoms are more likely to have
www.frontiersin.org December 2012 | Volume 3 | Article 542 | 5
Jelsone-Swain et al. Cognition and depression in ALS
CI (Gordon et al., 2011). To test this and the influence of physical
functioning on cognition, bulbar (questions 1–3) and limb (ques-
tions 4–9) functioning were derived from ALSFRS-r subscores.
These were entered into a linear regression analysis with over-
all cognitive performance as the outcome variable. A cognitive
performance summary score was calculated for each individual
by taking the summation of z-scores from each of the cogni-
tive test measure (M =−0.32, SD= 6.03). This model was not
significant, F(2, 19)= 1.50, p= 0.25, R2= 0.05. Bivariate correla-
tions (Pearson’s r) between physical symptoms and overall cogni-
tive performance were also not significant: bulbar p= 0.45, limb
p= 0.12.
Vegetative symptoms did not influence cognitive test scores
Another possible confound in a patient’s cognitive status could be
attributed to vegetative symptoms common in patients with ALS.
We therefore created a subscore of vegetative symptoms measured
within the BDI, and examined the effect of these symptoms on cog-
nitive test performance between patients and controls. Five ques-
tions from the BDI were used, described previously. A MANCOVA
was conducted to test the hypothesis that vegetative symptoms
may extraneously influence cognitive test performance. Diagno-
sis, education, and vegetative symptom subscores were entered
as independent variables. Because patients are more likely to be
affected by these symptoms due to physical weakness, we pre-
dicted that patients with ALS would be more negatively affected
compared to HCs; therefore an interaction term between diag-
nosis group and vegetative symptoms was also included in this
model.
This analysis showed no main effect for vegetative symp-
toms on cognitive performance, F(13, 12)= 1.31, p= 0.33,
η2= 0.59. However, vegetative symptoms did influence test per-
formance on the Digit Span backward scores between groups,
F(1, 24)= 5.25, p= 0.03, η2= 0.18. Even after accounting for
the possible effect of vegetative symptoms on cognitive per-
formance, there was still a main effect of diagnosis group,
F(13, 12)= 3.19, p= 0.03, η2= 0.78. As in the original analy-
sis, there was no effect of education, F(13, 12)= 1.06, p= 0.46,
η2= 0.54. Also, there was no interaction effect between vegeta-
tive symptoms and diagnosis group, F(13, 12)= 0.59, p= 0.82,
η2= 0.39.
Because only 14 patients completed the BDI, t -tests were
conducted to test for demographic variable differences between
patients with and without BDI data, and a MANOVA was con-
ducted to test for a main effect on cognitive test performance.
Age, education, disease duration, and progression rate (PR) did
not differ between groups. There were also no differences between
cognitive test scores. ALSFRS-r scores however approached signif-
icance, t (20)= 2.04, p= 0.06. The group who completed the BDI
had a mean ALSFRS-r score of 39 (SD= 4.46) whereas those with-
out had a mean ALSFRS-r score of 34 (SD= 8.98). Given the small
sample size, it is possible that there was not an effect for vegeta-
tive symptoms on cognition because patients in this analysis were
physically higher functioning. However, this importantly shows
that patients with less disease severity still have overall poorer
cognitive performance than HCs, independent of the effects of
vegetative symptoms.
DEPRESSIVE SYMPTOMS IN ALS IN RELATION TO DISEASE SEVERITY
AND COGNITION
Patients with ALS were not more clinically depressed than HCs
We tested the hypothesis that patients with ALS were more
depressed than the HC group by conducting independent sample
t -tests using scores from the GDS. ALS patient mean scores were
higher on the GDS than the HC group (see Table 2). Although
these differences were statistically significant, the mean scores did
not fall within clinical range for depression. When examining
individual depression scores, two participants in each group met
clinical criteria for possible mild depression as measured by the
GDS. Vegetative symptoms, measured from the BDI, reported by
patients were not different than the HC group.
Depressive scores correlated with progression rate (PR) and limb
dysfunction
The fourth major goal of this study was to determine if depres-
sive symptoms are related to disease severity in ALS. A correlation
analysis using Pearson’s r-coefficient was conducted comparing
GDS scores with PR. PR was calculated using the equation:
(PR) = (48 - ALSFRS-r Patients Score)
Months Since Symptoms Onset
(Kollewe et al., 2008)
This correlation was significant, r= 0.52, p= 0.02 (see
Figure 1). To further examine this relationship, the ALSFRS-r was
divided into three subscores measuring bulbar (questions 1–3),
limb (questions 4–9), and respiratory (questions 10–12) impair-
ment. Of these models, depression scores negatively correlated
with limb dysfunction, r =−0.72, p< 0.001 (Figure 2). Depres-
sion scores did not correlate with bulbar (p= 0.60) or respiratory
symptoms (p= 0.49), however it should be noted that the range
of bulbar and respiratory symptoms in our group was small.
FIGURE 1 | Scatter plot showing the significant correlation between
increased depressive scores from the GDS and faster progression rate
(calculated by the PR equation, n=19).
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FIGURE 2 | Scatter plot showing the significant correlation between
increased depressive scores from the GDS and decreased limb
function measured from the ALSFRS-r (n=19).
Depressive symptoms affect cognitive test performance
The final MANCOVA in this study was performed to test the
hypothesis that depressive symptoms have an influence on cogni-
tive test performance differentially in patients with ALS. Depres-
sion may negatively impact cognition, and we aimed to answer
whether ALS patients are more at risk for CI if they have comorbid
depressive symptoms. Therefore, an interaction variable between
GDS scores and diagnosis group and main effect variables of diag-
nosis group, GDS scores, and education were entered into the
MANCOVA to test for effects on cognitive test measurements from
the neuropsychological battery.
In this MANCOVA, there was a significant interaction effect
between GDS scores and diagnosis group, F(13, 17)= 2.90,
p= 0.02,η2= 0.69. As expected, there were significant main effects
of depressive symptoms, F(13, 17)= 3.34, p= 0.01, η2= 0.72 and
diagnosis group, F(13, 17)= 4.51, p< 0.01, η2= 0.78. Examin-
ing the univariate effects on each cognitive test separately, there
was interestingly not a significant main effect of depression on
any single cognitive test, although the HVLT delayed recall scores
approached significance, p= 0.07. There also was not a significant
univariate effect of the interaction variable on any single cogni-
tive test. Slopes of univariate analyses were examined to assess
which group was more affected by depression on each cogni-
tive test individually. Patients were more negatively affected by
depressive symptoms on six of the cognitive test measurements
(HVLT delayed recall, Faces II delayed recall, Oral Trails ratio,
Animal Naming test, JOLO, and BNT), whereas the HCs were
more negatively affected on five of the cognitive test measure-
ments (MMSE, HVLT immediate recall and discrimination, Faces
I immediate recall, and COWAT). This indicates there was not
a specific pattern of which group was overall more affected by
depressive symptoms, rather that the groups were indeed affected
differently on individual cognitive domains. For example, patients
appear more affected by depressive symptoms on tests of delayed
recall whereas HCs appear more affected on tests of immediate
recall.
DISCUSSION
There has been a recent push toward psychological interven-
tion for patients with ALS in order to improve overall quality
of life (Pagnini et al., 2012). Interventions would be better stream-
lined if risk factors for psychological distress were identified early,
including risks for cognitive dysfunction and depression. In this
study, we analyzed cognitive test performance between patients
with ALS and a healthy control population. Importantly, we
assessed the influence of physical and depressive symptoms on
cognitive functioning in ALS, which may lead to better screening
of individuals possibly at risk of having ALSci. We also exam-
ined depressive symptoms in patients with ALS, and assessed if
these depressive symptoms are related to disease progression or
the manifestation of physical dysfunction specific to the disease
process.
COGNITIVE PERFORMANCE DIFFERENCES BETWEEN PATIENTS WITH
ALS AND HEALTHY CONTROLS
Results from our study corroborate previous findings, support-
ing cognitive performance differences between patients with ALS
and HCs (Grossman et al., 2007; Strong et al., 2009). Overall,
patients performed more poorly on cognitive testing than HCs,
with specific deficits in executive function (verbal fluency) and
visual recognition memory. Among patients identified as having
ALSci, the majority had impaired scores in semantic fluency and
verbal learning and memory. Poorer performance in verbal fluency
was not confounded by speech production speed. These findings
are consistent with the literature, as verbal fluency remains the
most sensitive to ALS cognitive dysfunction, and many others have
noted impairment in memory and learning (Massman et al., 1996;
Strong et al., 1996, 1999; Abrahams et al., 1997, 2004; Hanagasi
et al., 2002; Grossman et al., 2007; Christidi et al., 2012). Utiliz-
ing neuropsychological tests that measure these cognitive domains
would be most beneficial to screen for cognitive decline in a multi-
disciplinary ALS clinic setting, and have already been implemented
in some clinics (Flaherty-Craig et al., 2009, 2011; Woolley et al.,
2010).
THE EFFECT OF PRIMARY AND SECONDARY PHYSICAL SYMPTOMS ON
COGNITION IN ALS
Results did not support a unique contribution of limb or bulbar
function on cognition. There has been no evidence that limb onset
or symptoms are related to CI, and our results support previous
research that found no specific effect of bulbar symptoms (Rip-
pon et al., 2006; Gordon et al., 2010; Rusina et al., 2010). However,
research on this is not consistent, and several studies have indi-
cated that those with bulbar onset are more likely to be cognitively
impaired (Lomen-Hoerth et al., 2003; Gordon et al., 2011). It may
be possible that higher reports of CI in these patients are partly
due to speech-motor impairment confounds, as a recent meta-
analysis of 554 non-demented individuals with ALS did not find
a relationship between CI and bulbar onset ALS (Raaphorst et al.,
2010). Although we did not find an effect of bulbar symptoms on
cognitive function, the number of patients with bulbar onset ALS
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were disproportionally less than those with limb onset, therefore
our study was limited in that we could not conduct a comparative
analysis between onset subtypes. Additionally, there was a small
range of scores for bulbar symptoms, as measured by questions
1–3 in the ALSFRS-r (see Table 1), which may have contributed to
our null result. Regardless, the involvement of bulbar symptoms
on cognition, if any, should be further investigated to establish
consensus.
One of our primary goals was to test whether vegetative symp-
toms confound or mask the interpretation of CI in ALS. Our
results indicate, however, that these symptoms did not contribute
to cognitive performance differences between patients with ALS
and HCs. Although against our hypothesis, these results suggest
that secondary physical symptoms, such as fatigue, collectively do
not interfere significantly with test performance in patients with
ALS. This finding was from a subgroup of patients in our study
with overall high physical functioning, suggesting that CI mani-
fests very early in the disease process. This finding supports ALSci
as a true variant of the disease, and increases the importance of
understanding CI in ALS.
RELATIONSHIP BETWEEN DEPRESSIVE SYMPTOMS, PHYSICAL
SYMPTOMS, AND COGNITION IN ALS
Depression contributes to decreased quality of life in patients with
ALS (Tramonti et al., 2012), however our study indicated that as a
group patients with ALS were no more likely to be depressed than
a HC population. Although these results are consistent with recent
reports (Averill et al., 2007; Atassi et al., 2011) that claim prevalence
rates of depression are low in ALS, our study was limited by a small
sample size and was not representative of a valid prevalence-rate
study. Importantly, we found that increased depressive symptoms
were associated with both disease progression and the severity
of limb dysfunction. Severe global physical dysfunction has been
shown to correlate with clinical depression (Oh et al., 2012), and
now this effect has been demonstrated in a physically high func-
tioning group without clinical depression (and using the revised
version of the ALSFRS). Additionally, this relationship was most
sensitive to limb dysfunction, suggesting those with more severe
limb impairment may be at most risk. Given these findings, in con-
junction with evidence for increased mortality risk in those with
psychological distress (McDonald et al., 1994), future research on
depression treatment and its association with survival should be
emphasized.
Another important finding from our study indicates that
depressive symptoms had an effect on cognitive performance.
Although novel in the ALS literature, the relationship between
depression and cognition has been demonstrated among other
diseases (Diamond et al., 2008), and it has even been suggested
that depression treatment could lead to improved cognitive per-
formance (Sassoon et al., 2012). Likewise, a recent meta-analysis
found that cognition can predict depression status, which could
be targeted to increase treatment efficacy for depression (Phillips
et al., 2010). Although there are no reports of depression treatment
improving cognitive functioning or vise versa in ALS, these could
potentially become important avenues for future translational
research.
LIMITATIONS AND CONCLUSIONS
Limitations
A major limitation in our study is that we were not able to test
other factors that have been found to influence cognitive per-
formance in patients with ALS. For example, Kim et al. (2007)
found that patients with reduced forced vital capacity (FCV)
performed significantly worse on tasks measuring memory reten-
tion/retrieval and verbal fluency than patients with normal vital
capacity. Moreover, it has been suggested that impaired cogni-
tion might be reversible to some degree with increased vital
capacity (Kim et al., 2007; Strutt et al., 2012). We suspect that
patients in our study did not have impaired FVC for two rea-
sons: they were enrolled in an MRI study and therefore able
to lay flat on their back for more than 1 hour without res-
piratory distress, and scored near maximum on the ALSFRS-r
questions measuring respiratory symptoms. Regardless, we did
not explicitly acquire FVC measurements and were therefore
unable to take into account this possible confound in our
data.
Similarly, pseudobulbar affect is another symptom that may
have a differential effect on cognition, and previous research has
suggested that those with this symptom may be more at risk for
CI (Abrahams et al., 1997). Again, we did not measure pseudobul-
bar affect symptoms and are therefore unable to account for this
possible influence on cognition.
Our study also lacks a causal interpretation. We found that
depressive symptoms and cognitive performance are related, but
because we were unable to manipulate depressive symptoms or
cognitive performance we were unable to identify the exact direc-
tion of this relationship. Additionally, our study showed that
depressive symptoms are related to disease progression and limb
dysfunction, yet it cannot be concluded whether increased depres-
sive symptoms caused or directly influenced disease state. It is
suggested that future studies examine depression and cognition
intervention in order to identify a directional change in either
disease state or cognitive performance.
Another major limitation in our study is the small sample size
of groups. It is common for studies examining cognitive perfor-
mance to include more than 100 participants, yet our study only
compared 22 patients to 17 HCs. This is often a limitation in many
rare disease population studies, however, and is especially com-
mon in the ALS literature. Future research would benefit from
multicenter pooling of data, as suggested by Turner et al. (2011),
in order to acquire larger sample sizes and gain higher statistical
power.
In line with our small sample size, our analysis examining the
effect of vegetative symptoms on cognition between groups was
especially limited because only 14 patients completed the BDI.
Those who completed the BDI were less severe in their disease
symptoms. This analysis cannot therefore be generalized to the
whole group in our study. However, this importantly shows that
patients with less disease severity still have overall poorer cogni-
tive performance than HCs, strengthening the finding that CI is a
true symptom of ALS. The role of vegetative symptoms should be
further explored, including larger sample sizes and patients with
varying degrees of disease severity.
Frontiers in Psychology | Psychology for Clinical Settings December 2012 | Volume 3 | Article 542 | 8
Jelsone-Swain et al. Cognition and depression in ALS
Conclusions
Overall, this study supported previous findings that CI is a symp-
tom in approximately 35% of patients with ALS, and that patients
overall perform worse than HCs in tests of executive dysfunc-
tion and learning and memory. Cognitive performance differ-
ences remained after accounting for variables including vegeta-
tive symptoms, physical dysfunction, and depressive symptoms.
Additionally, we report that increased depressive symptoms are
related to faster disease progression and greater limb dysfunction
in patients with ALS. We therefore suggest that future research
investigate the effects of depression therapy in patient care.
Although CI can significantly contribute to decreased qual-
ity of life for patients with ALS, research in this area is limited
and often lacks a translational emphasis. Importantly, there is
currently no treatment for patients who suffer from CI in ALS.
Research though has highlighted several avenues to pursue in
investigating CI intervention, including improving FVC (Kim
et al., 2007; Strutt et al., 2012), treating pseudobulbar affect (Abra-
hams et al., 1997), and now therapy for depressive symptoms.
Conversely, CI treatment may also improve depressive symptoms.
We emphasize that future research focus on effective psychological
or clinical interventions that may improve quality of life caused by
CI or depression, and that these interventions be applied in future
multidisciplinary ALS clinics.
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